公开(公告)号：US20190330321A1

公开(公告)日：2019-10-31

申请号：US16307444

申请日：2017-06-07

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene BON ,  Joanne Elizabeth COMPSON ,  Kate Louise DIXON ,  Carl Brendan DOYLE ,  Mark ELLIS ,  Maria Margarida GOUVEIA SANCHO ,  Raymond Anthony JUPP ,  Lara KEVORKIAN ,  Daniel John LIGHTWOOD ,  Diane MARSHALL ,  Andrew Charles PAYNE ,  Joseph Michael David RASTRICK ,  Monika-Sarah SCHULZE ,  Alison TURNER ,  Kerry Louise TYSON

IPC: C07K16/22 ,  A61K9/00 ,  A61P11/00

Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.

公开(公告)号：US20190330327A1

公开(公告)日：2019-10-31

申请号：US16470999

申请日：2017-12-13

Applicant: UCB BIOPHARMA SPRL ,  SANOFI

Inventor： Alastair David Griffiths LAWSON ,  Daniel John LIGHTWOOD ,  Rebecca Jayne MUNRO ,  James Philip O'CONNELL ,  John Robert PORTER

IPC: C07K16/24

Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.

公开(公告)号：US20180171008A1

公开(公告)日：2018-06-21

申请号：US15736535

申请日：2015-10-22

Applicant: UCB Biopharma SPRL

Inventor： James Philip O'CONNELL ,  John Robert PORTER ,  Alastair LAWSON ,  Daniel John LIGHTWOOD ,  Rebecca Jayne WOOTTON

IPC: C07K16/24 ,  G01N33/68

CPC classification number: G01N33/6845 ,  A61K47/6425 ,  A61P35/00 ,  A61P37/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D401/14 ,  C07D471/00 ,  C07D471/04 ,  C07K14/525 ,  C07K14/70575 ,  C07K16/241 ,  C07K2317/55 ,  C07K2317/92 ,  G01N33/6854 ,  G01N33/6863 ,  G01N2333/525 ,  G01N2500/02

Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.

公开(公告)号：US20180172701A1

公开(公告)日：2018-06-21

申请号：US15736558

申请日：2015-10-22

Applicant: UCB Biopharma SPRL ,  SANOFI

Inventor： James Philip O'CONNELL ,  John Robert PORTER ,  Alastair LAWSON ,  Tracy Lynn ARAKAKI ,  Daniel John LIGHTWOOD ,  Rebecca Jayne WOOTTON

IPC: G01N33/68 ,  C07D401/14 ,  C07D239/26 ,  C07D235/04 ,  C07D213/72 ,  C07K14/525 ,  C07K14/705 ,  C07K16/24 ,  C07D471/04

CPC classification number: G01N33/6845 ,  A61K47/6425 ,  A61P35/00 ,  A61P37/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D401/14 ,  C07D471/00 ,  C07D471/04 ,  C07K14/525 ,  C07K14/70575 ,  C07K16/241 ,  C07K2317/55 ,  C07K2317/92 ,  G01N33/6854 ,  G01N33/6863 ,  G01N2333/525 ,  G01N2500/02

Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.

公开(公告)号：US20180231562A1

公开(公告)日：2018-08-16

申请号：US15736614

申请日：2015-10-22

Applicant: UCB Biopharma SPRL

Inventor： James Philip O'CONNELL ,  John Robert PORTER ,  Alastair LAWSON ,  Boris KROEPLIEN ,  Stephen Edward RAPECKI ,  Timothy John NORMAN ,  Graham John WARRELLOW ,  Tracy Lynn ARAKAKI ,  Alex Buntin BURGIN ,  William Ross PITT ,  Mark Daniel CALMIANO ,  David Andreas SCHUBERT ,  Daniel John LIGHTWOOD ,  Rebecca Jayne WOOTTON

IPC: G01N33/68 ,  C07K14/525 ,  C07K16/24 ,  C07D401/14 ,  C07D471/00 ,  A61P35/00 ,  A61P37/00

Abstract: A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.